FindTrial
Sign In

Comparison between tofacitinib ointment with betamethasone valerate cream on skin of vitiligo patient

Evaluate Efficacy and safety of 2 percent topical tofacitinib versus 0.05 percent topical betamethasone valerate in treatment of vitiligo among patients attending tertiary care hospital bhavnagar a simple randomized controlled study - NILL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076957
Enrollment
30
Registered
2024-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: 2% topical tofacitinib ointment: Local application twice a day for 2 months Control Intervention1: 0.05% topical betamethasone valerate cream: Local application twice a day for 2 months

Sponsors

DR NIRBHAY DAMOR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of age more than 2 yrs of either gender presenting with less than five depigmented patches with size not exceeding 10 × 10 CM

Exclusion criteria

Exclusion criteria: Patient of vitiligo who have taken treatment in past 3 months. Patient of vitiligo with any other dermatology disorder. Patient of vitiligo with site involving mucosal, genital, perianal regions and face lesion

Design outcomes

Primary

MeasureTime frame
TO COMPARE VASI(vitiligo area scoring index)Timepoint: outcome will be assessed at baseline,1 month,2 month—

Secondary

MeasureTime frame
Vitiligo Noticeability Scale (VNS) and Percentage repigmentationTimepoint: 2 MONTHS—

Countries

India

Contacts

Public ContactDR NIRBHAY DAMOR

Government medical college,bhavnagar

hitamehta88@gmail.com9429503188

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026